Lexicon Pharmaceuticals (LXRX) Asset Writedowns and Impairment (2010 - 2020)
Lexicon Pharmaceuticals (LXRX) posted quarterly Asset Writedowns and Impairment of $1.6 million for Q2 2020, up 105.59% quarter-over-quarter from -$28.6 million in Q4 2019.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Asset Writedowns and Impairment (2010 - 2020) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Asset Writedowns and Impairment for 6 consecutive years, with $1.6 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million; the TTM figure through Sep 2021 stood at $1.6 million (changed 0.0% YoY), while the FY2020 annual figure was $1.6 million, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $1.6 million in Q2 2020 per LXRX's latest filing, from -$28.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $28.6 million in Q3 2019 and bottomed at -$28.6 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 1.60 Mn |
| Sep 30, 2019 | 28.64 Mn |
| Dec 31, 2015 | 1.25 Mn |
| Sep 30, 2015 | 2.35 Mn |
| Dec 31, 2014 | 200,000.00 |
| Sep 30, 2014 | 13.10 Mn |
| Mar 31, 2014 | 242,000.00 |
| Dec 31, 2011 | -2,000.00 |
| Sep 30, 2011 | -79,000.00 |
| Jun 30, 2011 | 16,000.00 |
| Mar 31, 2011 | 769,000.00 |
| Dec 31, 2010 | 951,000.00 |
| Sep 30, 2010 | 50,000.00 |